Sinopharm Group Co (HKSE:01099) Accounts Payable & Accrued Expense : HK$183,148 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Accounts Payable & Accrued Expense?

Sinopharm Group Co's quarterly accounts payable & accrued expense declined from Jun. 2023 (HK$176,055 Mil) to Sep. 2023 (HK$0 Mil) but then increased from Sep. 2023 (HK$0 Mil) to Dec. 2023 (HK$183,148 Mil).

Sinopharm Group Co's annual accounts payable & accrued expense declined from Dec. 2021 (HK$177,398 Mil) to Dec. 2022 (HK$176,863 Mil) but then increased from Dec. 2022 (HK$176,863 Mil) to Dec. 2023 (HK$183,148 Mil).

Sinopharm Group Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sinopharm Group Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Accounts Payable & Accrued Expense Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

132,166.02

152,599.35

177,397.92

176,862.76

183,148.25

Sinopharm Group Co Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															176,862.76	176,055.36	-	183,148.25	-

Sinopharm Group Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sinopharm Group Co (HKSE:01099) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (HKSE:01099) Headlines

No Headlines